Alnylam Pharmaceuticals ALNY Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 330.7%-5.3pp | 336%-4.6pp | 340.6%-2.8pp | 343.4%-4.5pp | 347.8%+0.3pp | |
| Operating margin | 32%+22.5pp | 9.5%+21.4pp | -11.9%+17.2pp | -29.1%-11.7pp | -17.4%+3.9pp | |
| Net margin | 10.4%+21.5pp | -11.1%+19.9pp | -31%+18.4pp | -49.4%-8.3pp | -41.2%+6.8pp | |
| EBITDA margin | 38.8%+21.3pp | 17.5%+20.4pp | -2.8%+16.3pp | -19.1%-11.8pp | -7.4%+3.6pp | |
| Free cash flow margin | 32.3%+18.3pp | 14%+14.4pp | -0.4%— | —— | —— | |
| Returns | ||||||
| Return on assets | 12.1%+16.5pp | -4.4%+12.9pp | -17.3%+10.1pp | -27.4%-4.6pp | -22.9%+3.5pp | |
| Efficiency | ||||||
| Asset turnover | 3×+0.3× | 2.7×+0.2× | 2.4×+0.2× | 2.2×-0.1× | 2.3×0.0× | |
| Inventory turnover | 31.2×+6.9× | 24.3×+4.7× | 19.6×+3.6× | 16×+2.1× | 13.9×+1.5× | |
| Liquidity | ||||||
| Current ratio | 11.2×+0.1× | 11.1×0.0× | 11.2×-0.2× | 11.4×-0.2× | 11.6×-0.1× | |
| Quick ratio | 11×+0.1× | 10.9×0.0× | 10.9×-0.2× | 11.1×-0.2× | 11.3×-0.1× | |
| Cash ratio | 4.2×+0.3× | 3.9×+0.3× | 3.6×+0.1× | 3.5×-0.1× | 3.6×+0.2× | |
| Leverage | ||||||
| Debt-to-equity | 2.8×-0.4× | 3.2×-3.7× | 6.9×-7.5× | 14.4×— | —— | |
| Debt-to-assets | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.3×0.0× | 0.3×0.0× | |
| Interest coverage | 6.2×+4.1× | 2.1×+3.7× | -1.5×+2.9× | -4.4×-1.8× | -2.6×+0.7× | |
| Per Share | ||||||
| Book value per share | $17.26+35.2% | $12.77+71.8% | $7.43+24.3% | $5.98+48.1% | $4.04+510% | |
| Valuation | ||||||
| Market capitalization | $198.56B+4.7% | $189.63B+13.2% | $167.45B+17.1% | $142.98B+8.9% | $131.34B+14.0% | |
| Enterprise value | $193.66B+4.4% | $185.43B+13.1% | $163.93B+17.2% | $139.87B+8.9% | $128.39B+14.0% | |
| Price / sales | 60.2×-4.6× | 64.9×+0.6× | 64.2×+1.8× | 62.5×+4.1× | 58.3×+5.5× | |
| Price / book | 532×-41.2× | 573.2×-386× | 959.1×-836× | 1,794.8×— | —— | |
| EV / sales | 58.8×-4.7× | 63.4×+0.6× | 62.9×+1.8× | 61.1×+4.1× | 57×+5.4× | |
| Free cash flow yield | 2.6%+1.7pp | 0.9%+1.0pp | -0.1%— | —— | —— | |
| Earnings yield | 1.2%+1.8pp | -0.7%+1.4pp | -2.1%+1.1pp | -3.2%-0.4pp | -2.8%+1.1pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Alnylam Pharmaceuticals's profit margins?
- Alnylam Pharmaceuticals (ALNY) runs a 81.0% gross margin and a 17.5% operating margin, with a 11.7% net margin.
- Where do Alnylam Pharmaceuticals's ratios come from?
- Every ratio is computed from Alnylam Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
